Ultragenyx Pharmaceutical (NASDAQ:RARE) Issues Quarterly Earnings Results, Misses Expectations By $0.36 EPS

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($2.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.97) by ($0.36), Briefing.com reports. The business had revenue of $100.50 million for the quarter, compared to the consensus estimate of $103.90 million. Ultragenyx Pharmaceutical […]

Related Keywords

Blackrock ,New Zealand General ,New Zealand ,Wellington ,Theodore Alan Huizenga ,Emild Kakkis ,Robertw Baird ,Camillel Bedrosian ,Blackrock Inc ,Vanguard Group Inc ,Wellington Management Group ,Ultragenyx Pharmaceutical Inc ,Clearbridge Investments ,Credit Suisse Group ,Cantor Fitzgerald ,Morgan Stanley ,Canaccord Genuity Group ,Ultragenyx Pharmaceutical Company Profile ,Ultragenyx Pharmaceutical ,Get Rating ,Alan Huizenga ,Management Group ,State Street Corp ,Street Corp ,Suisse Group ,Genuity Group ,Ultragenyx Pharmaceutical Daily ,Nasdaq Rare ,Rare ,Medical ,Earnings ,